Nyxoah SA (NYXH): Price and Financial Metrics
GET POWR RATINGS... FREE!
NYXH Stock Price Chart Interactive Chart >
NYXH Price/Volume Stats
| Current price | $5.84 | 52-week high | $23.05 |
| Prev. close | $5.75 | 52-week low | $5.36 |
| Day low | $5.77 | Volume | 4,700 |
| Day high | $5.90 | Avg. volume | 5,352 |
| 50-day MA | $6.21 | Dividend yield | N/A |
| 200-day MA | $12.72 | Market Cap | 145.67M |
Nyxoah SA (NYXH) Company Bio
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest NYXH News From Around the Web
Below are the latest news stories about NYXOAH SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 17, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 2 |
Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Nyxoah Reports Third Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results DREAM US pivotal 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – November 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the quar |
Nyxoah Announces Change to Board of DirectorsNyxoah Announces Change to Board of Directors Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022. About NyxoahNyxoah is a medical technology |
Nyxoah to Participate in the Jefferies London Healthcare ConferenceNyxoah to Participate in the Jefferies London Healthcare Conference Mont-Saint-Guibert, Belgium – October 20, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The |
NYXH Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -71.10% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -74.61% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...